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pM DHPG combinated with 5 U / d  IFN (Y and 95 f 5% inhibition 
with 1 l . lpM DHPG in combination with 0.2 ng/d IFN y (n = 3). 
Conclusions: IFN (Y and IFN y decrease HCMV infection in 
monocytic-like cell line THP-1 and may lead to an improvement of 
the available chemotherapy against this important human pathogen. 
Combination of IFNs with DHPG after lnfection showed a syner- 
gistic effect. 
I P103q Activity of Penciclovir (PCV) in vitro against 
Cytomegalovirus (CMV) Wild Strains (WS) and 
against Strain AD169 
B. Hostettler, E? Jordan, G. Cathomas, R. Attenhofer, E? Reusser. 
University Hospital, &el, Switzerland 
PCV has a well-documented inhibitory activity against herpes sim- 
plex virus and varicelia-zoster virus. By contrast, data on its activity 
against CMV are limited. We evaluated the in vim activity of PCV 
against 3 CMV WS (#1 and #2 from marmw transplant recipients, 
#3 from a neonate) and against CMV s t r a i n  AD169, and compared 
the results with those obtained in parallel with acyclovir (ACV), 
ganciclovir (GCV), and foscarnet (FOS). A plaque reduction assay 
was used to determine the mhibitory drug concentration reducing 
plaque numbers by 50% (IC50). The drugs were tested in 6 human 
fibroblast cell lines. The results were as follows: 
Me& (nnge) 1c50 in pM 
WS#I WS#2 WS#3 C M V  AD169 
PCV 182 (13P188) 232 (5S266) 87 (72-102) 101 (68-118) 
ACV 45(29-68) 31 (18-54) 26 (24-27) 40 (28-56) 
GCV § 3 (2.65) 2 (1-3) 3 (1-5) 
FOS 75 (4S114) 73 (47-116) 106 (72-140) 75 (58-119) 
Median ICsg of 13 p M  (630) indxatmg a rerkunce to ganclclovlr. 
The pooled ICsos of PCV (all CMV strains) were significantly 
higher than those of ACV, GCV, and FOS (P < 0.0001 for each 
comparison). However, the ICs0 values obtained must also be con- 
sidered in the context of the pharmacokinetic and toxicologic prop- 
erties of the drugs tested, and the activity of PCV against CMV 
should be further investigated in vivo. 
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I P1033 I lnfection in Immunosuppressed Patients after 
Bone Marrow Transplantation (BMT) 
V. Tchebotkevitch, S. Moiseev, K. Abdoulkadirov. Russian Incfifute 
of Haemofology nnd Ezrnjhsiology, Sf-Petersbutg, Russia 
Twelve patients with different forms of haematological malignancies 
underwent autologous (n = 6) or allogeneic (n = 6) BMT were 
tested. The materials (blood sera and nasal swabs) were collected 
each 2 weeks during 6 months in pre- and post-transplantation pe- 
riod. Nasal swabs were washed with l ml PBS and the material was 
subjected to sedimentation. The sedimented nasal epithelium cells 
were used for direct immunofluorescence (IF) microscopy, which 
was performed with fluorescein-conjugated antibodies (Abs) to res- 
piratory viruses and Mycoplatma pneumoniae (Mp). The supernatant 
was used for detection of mucosal Abs. The detection of these Abs 
as well as Abs in blood sera was performed in Indirect Haemag- 
glutination Test (IHA) with viral (Injuenra fypes 1, 2 and 3, Aden- 
ovinrs, Rezpirntory syn6tial virus, Coronavincc) and Mp antigens. Bacte- 
rial and fungal infections were diagnosed microbiologically In all 56 
episodes of infection were diagnosed. In 54 of these episodes mixed 
Mp-viral infection was demonstrated. Twenty five (45%) episodes 
were detected in immunosuppressed patients during the period of 
profound neutropenia immediately after BMT. The clinical mani- 
festations of invasive bacterial infections caused by Eschm’chia coli, 
Mebsiella pneumoniae and Pseudomom amginosa were more severe 111 
the episodes of preexisting respiratory viral- Mp infection. So the 
viral-mycoplasmal respiratory infection decreases the resistance to 
bacteria in immunosuppressed patients. The immune response in the 
patients was characterized by dramatic decrease in blood Abs level 
whereas the mucosal Abs changed similarly to those in immuno- 
competent patients. We conclude that viral-mycoplasmal infection 
enhances the immunodepression in immunosuppressed patients es- 
pecially the general immune response rather than the local one and 
these infections must be caremy controlled. 
1-1 CMV Management to Prevent Related Allograft 
Deterioration 
U. Jacobs, D. Niese, H.-U. Klehr. Medical Dept, Univenify Hosp, 
Bonn, Germ 
Objectives: Enhanced allogenity by CMV may induce acute rejec- 
tions as well as chronic transplant (TP) damage via endothelial and 
mitogenic lesions. 
Methods: In a subset of 113 renal allografted patients (P) we 
analysed CMV incidence, onset, risk profile and evaluated earliness 
and sensitivity of cytoimmunological (lymphocyte subsets by FACS) 
and viral diagnostic work-up weekly after TX (pp65-early antigen 
(EA) (+ PCR) + CMV-IgM-titer (ELJSA techn.) + virus isolation 
in urine and throat swab), as well as the impact of early virustatic in- 
tervention on acute and long-term TP function and suMval. CMV 
disease defined as combination of one viral parameter plus organ 
deterioration. 
Results: Incidence of CMV disease was 31% posttransplant, 58% 
of all associated with monoclonal antibody therapy (OKT3) for acute 
rejection. Independently of recipient status pretransplant positive 
donor CMVIgG increased risk of disease up to 70%. In addition 
to earliness diagnostic sensitivity of CD4/CD8 inversion (93%) was 
> pp-65 early antigen (56%) > IgM seroconversion (33%) > virus 
isolation (10%). In P with recurrent CMV disease PCR was more a 
marker for lnfection regardless of disease. Leucocytes decreased from 
8.6 f 1.4 to 4.2 f 1.8/nl. Clinally the predictive value of a charac- 
teristic nocturnal hyperhidrosis all P with CMV disease complained 
about was accompanied with the CD4/CD8 inversion-decrease of 
CD4-lymphocytes and increase of CD8-lymphocytes resulting in a 
ratio <1-even preceding acute organ deterioration. The degree of 
inversion reflected severity of CMV disease course and the diagnostic 
value of this parameter was not impaired even in P on monoclonal 
antibodies. Consequent virustatic therapy contributed to improve- 
ment of transplant function with decrease of serum-creatinine &om 
3.2 f 1.2 to 1.6 f 0.5 mg/dl. There were no adverse effects associ- 
ated with ganciclovir and no drug resistance. One year graft suMval 
was improved up to 97% without any CMV complication. Statistical 
analysis after 2.7 f 1.2 yrs follow-up period excluded any remaining 
impact of previous CMV disease on longterm TP function (actuarial 
creatinine and proteinuria). 
Conclusions: Despite high incidence and varying time of on- 
set esp for primary CMV posttransplant adequate CMV monitoring 
guarantees earliest diagnosis. The trias of symptoms: CD4/CD8 in- 
version, nocturnal hyperhidrosis and leucocyte decrease are reliable 
and most sensitive predictors. Consequent virustatic treatment con- 
mbutes to impressive amelioration of transplant suMval and even 
prevention of long-term graff damage as it might result h m  unde- 
tected CMV disease on a chronic base. 
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m] Human-Herpes-Vims-6 Associated Severe 
U. Jacobs, H.-U. Klehr. Medical Department, University Hospitnl, 
Bonn, Germany 
Objective: Renal transplant survival rate could be improved up to 
96% throughout the last 3 years in our transplant care unit due to 
efficacy of OKT-3 in steroid resistant acute rejection episodes and 
early intervention in CMV infection often knked to this strong im- 
munosuppressive regime. But there is only small experience with 
reactivation of HHV-6 infection in transplantation esp. for its treat- 
ment. 
Case Report: We therefore report on a 66 y old male patient 
@) sufTering from a severe dection with fever up to 4loC, leucope- 
nia, fatigue and transplant dysfunction 13 weeks after allografang. 
He had overcome 3 rejection episodes treated with cortisone, ATG 
and OKT-3 twice resp.. A primary CMV infection transmitted by 
positive donor transplant manifestated after the hrst OKT-3 course 
requiring ganciclovir. Now by weekly wal work-up CMV reacti- 
vation could be excluded. But there was evidence for a strong viral 
infection from conthously decreasing CD4/CD8 inversion within 
lymphocyte subsets. By means of standardued weekly viral monitor- 
ing HHV-6-IgM antibodies were detected fluorescenceserologically 
to a high degree for the first time. Up to that date the p was only 
known to be HHV-6-XgG positive. 
Sirmkr to CMV infection there is strong serological evidence of 
wide-spread HHV-6 lnfection in the general population, but, so far, 
the only disease definitely h k e d  to HHV-6 is exanthema subitum in 
chlldhood and therapeutic effects of antiviral agents have been tested 
only in vim. In our p by the onset and consequently virustatic 
treatment with gancidovir the allograft function could be improved 
after IgM-seroconversion was overcome. Serum-creatinine decreased 
h m  448 to 131 wmol/L and leucocytes recovered. In the one year 
follow-up now a stable renal transplant function under conventional 
thempy with cyclosporine, steroids and azathioprine is maintained. 
Conclusions: Repeated dosage regime of OKT-3 may trigger 
severe HHV-6 infection reactivation resulting in transplant damage. 
Daerential bgnosis should focus on rhu, virus in transplantation esp 
after exclusion of CMV Ganciclovir revealed to be a potent antiviral 
agent in HHV-6 infection in vivo. 
Allograft Dysfunction 
(P1036j Cytomegalovirus Infection in Renal Transplant 
A.M. Vedjakov, M.S. Dolgkh, ES. Baranova. Institute Of 
Transplanfotogy E. Artifinal Organs, Moscow, Russia 
Objectives: to compare the results of cytomegalovirus (CMV) 
DNA detections in blood, saliva and urine, anti-CMV antibodies 
IgM for prognosis of CMV disease. 
Methods: DNA h m  leukocytes was isolated by glass beads. A 
semiquantitative nested polymerase chain reaction (PCR) with two 
sets of primers to M E  region was used. The sensitivity of PCR was 
5-10 copies of viral genom. IgM were determined by ELISA. 
Results: Samples (blood, saliva and urine) of 16 patients after 
transplantations (1-3 months) were investigated. These patients had 
no acute symptoms of CMV-disease, but had minor unclear c h c a l  
symptoms. 8 patients had CMV DNA in blood by PCR <lo0 
copies in lo5 leukocytes. 6 (75%) h m  these had CMV DNA in 
urine and 5 (62%) also in saliva. 2 of these fell in CMV-disease later 
with rising of CMV DNA level. Among 8 others PCR-negative in 
blood patients 4 had CMV DNA in urine and in saliva. 3 of these 
4 padents were after effective ganciclovir therapy. Others 4 had no 
CMV DNA neither in urine nor in saliva. That patients, who had 
no or very low DNA signal in blood, had intensive DNA signal 
Recipients 
in urine or saliva, if it was. IgM positive were 2 patients, who had 
anti-CMV drug therapy early. 
Conclusions: The results obtained by PCR in blood of patients 
without acute onset of CMV-disease, don’t coincide with that in 
urine and saliva. CMV DNA present in Werent biological materials. 
In urine and in saliva the amounts of viral DNA were essential, but in 
blood the levels of CMV DNA without symptoms of CMV-base 
in patients were very low. The semiquantitative detection of CMV 
DNA in blood is more successful for &ease diagnosis than in urine 
and in saliva. 
(p10371 Monitoring of Cytomegalovirus Infected 
Patients after Renal, Heart and Bone Marrow 
Transplantation by PCR and ELISA 
M.S. Dolg~kh, A.M. Vedjakov, ES. Baranova. Institute cf 
Transplantology G Artlf”a1 Organs, Moscow, Russia 
Objectives: the diagnosis of active cytomegalovirus (CMV) infec- 
tion and monitoring of therapy by polymerase chain reaction (PCR) 
and ELISA. 
Methods: DNA from leukocytes was isolated by glass beads. A 
semiquantitative nested PCR with two sets of primers to M E  region 
was used. The sensitivity of PCR was 5-10 copies of viral DNA. IgG 
and IgM were determined by ELISA. 
Results: 72 patients (67-renal, 3-heart, 2-BMT) were investigated 
29 patients were CMV-positive by PCR. The quantity of CMV 
DNA correlated with clinical manifestations. 9 patients with more 
than 1000 copies of viral DNA in lo5 leukocytes had acute CMV 
disease. The blood samples h m  patients with active CMV-infection 
were drawn in intervals 4-14 days after transplantation. 6 from 8 
patients with 100-1000 copies had subfebrile temperature andlor 
gastrointestinal symptoms. After effective ganciclovir therapy wal 
DNA cleaned as a rule. But in 4 patients without clin~cal symptoms 
CMV DNA was detected 2 4  months after. IgM and IgG antibodies 
correlated with CMV disease badly. Among anti-CMV IgM-positive 
samples 42.3% were PCR-positive, and among IgM-negative sam- 
ples 31.8% were PCR-positive @ > 0.05). IgM antibodies and CMV 
DNA in blood of the patient with BMT were detected during 2 
months after finish of drug therapy without rise of IgG antibody 
titres and without clinical symptoms. These IgM antibodies also ap- 
peared 4 weeks later, than CMV DNA at the onset of disease. 
Conclusions: PCR is direct and very sensitive method for diag- 
nosis of active CMV mfection. The amount of CMV DNA >lo00 
copies in lo5 leukocytes correlated with CMV disease. IgM and IgG 
detection had low &agnostic value. 
I P1038 1 Do Children with Lymphoproliirative Diseases 
during Chemotherapy Aquire Hepatitis C V~NS 
Infeetion? 
J.S. N o d ’ ,  D. Januszkiewicz’ ’. ‘Institute $Human Generia, 
PoZish Academy Of Sciences, Poznati, Poland, ’Institute of Pediahirs 
University OfMedical Sciences, Poznati, Poland 
Objectives: To estimate the incidence rate of HCV infection and 
to analyze the HCV genoeypes in three-year-follow-up study of 
cMdren with leukemias and lymphomas undergoing chemotherapy. 
Methods: The studied group consisted of 148 children, without 
HCV antibodies (HCVAb) at the time of the diagnosis. HCVAbs 
were estimated with EIA test of IInd generation (Organon Tekmka) 
Presence of HCV-RNA partides and their genotypes were detected 
by nested PCR method and line probe assay (Inno-Lipa HCV 11). 
Results: The appearance of HCVAb during therapy was observed 
in 42 patients (28.4%), in median time 14 months after dmgnosis. 
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Among 42 children with positive HCVAb, in 36 patients (85.7%) 
RNA-HCV was confirmed by PCR result in every examination. 
34 of HCV-FWA positive cases were infected with HCV with a 
slngle genotype, includmg type la in 31 chddren and type lb  in 2 
patients. Coinfection with two genotypes of HCV was observed in 
two patients (la+lb). None of the HCV-RNA positive childsen has 
became negative during 3-year-follow-up study. 
Conclusions: Persistence of viremia in the HCV-mfected patients 
can be explained by the therapy-induced immunosuppression. The 
same HCV genotype in almost 90% of analyzed children strongly 
suggest the common source of HCV lnfection The infectivity of 
those children should be seriously considered during chemotherapy. 
This work has been sponsored by KBN grant No 4POSE 029 08. 
Fl Influence of Prolonged Antiviral Prophylaxis in 
F! Vallejo, L. Cardeiioso, S .  Lbpez, R. C h a m ,  J.L. Ro&, 
M. Lbpez-Brea. Hospital de la Princess, Madrid, Spain 
Cytomegalovirus (CMV) lnfection remains the most frequent mfec- 
tion after allogeneic bone marrow transplant (ABMT). Demonstra- 
tion of CMV in clinical samples is the principal approach for the 
diagnosis of CMV infection. 
Objective: To determine whether the use of prolonged antiviral 
prophylaxis affect the detection of CMV by shell vial assay (SVA) and 
conventional cell culture (CC) in surveillance specimens after ABMT. 
Methods: A total of 72 patients with ABMT (CMV sero+ and/or 
donor sero+) were prospectively monitored during 22 weeks for the 
detection of CMV in blood, urine, throat and bronchoalveolar lavage 
(BAL) by SVA and CC in MRC-5 cell line. Of these, 42 received 
high dose acyclovlr (HD ACV) (500 mg/8 h) from day -5 to +30 
after BMT (Group A); and 30 received HD ACV from day -5 to 
+30 and then, or dadclovir (2 g/6 h) or ACV oral (800 mg/6 h) 
up to the week 18 post BMT (Group B). These 30 patients were 
enrolled in a prospective trlal to compare both antiviral prophyhs. 
the Detection of CMV after Allogeneic BMT 
Results: 
Pancnrr Sampler SnmpierCMV+ SVA+ CCt 
~ 
GroupA 42 1313 40 (3%) 26 (65%) 29 (72.5%) 
GroupB 30 1751 15 (09%) 9 (60%) 7 (46.7%) 
Conclusions: The prolonged use of prophylaxis antiviral after 
ABMT reduces sigdcatively (p c 0.05) the detection of CMV in 
surveillance specimens. Sensitivity of CC decrease in specimens h m  
patients with prolonged antiviral prophylaxis. 
I PI040 I Viral Complications after Renal 
F! Lazarova ', Kr. Metodiev ', H. Ben-Bassat ' ,  N. Kolesnick 3. 
'Mediral University, krna, Bulgaria, 'Hadassah Medical Center, 
Jmsalem, Israel, 31mt. Urology G. Nephroloa, Kiev, Ukraine 
Major problem after renal allohansplantations are both, rejection 
crises and infectious complications, requiring rather a e r e n t  
therapeutical behaviour. The infections could be of various origin; 
however, those with wal etiology are bigger problem for transplan- 
tologists, nephrologists, immunologists and of course for the patients 
themselves. The authors of present study examine dynarmcally 78 
recipients of renal allografts by using the method of immunologic 
monitoring, also microbiologic, virologic and biologic tests, as 
well as the inhence of immunomodulation and antiviral therapy. 
Altogether 64 infectious complications are registered during the 
first 3 months after transplantation €or all patients. 38 of 64 (59%) 
Allotransplantation 
infections have viral origin and their etiology is as follows: 13 (of 38) 
hepatitis, 11 duenza ,  6 CMV, 2 adenovd, 2 ECHO, 2 herpes, 
2 HIV (1 seropositive and 1 virus-carrier). It is worth-mentioning 
that our long-term study covers a period of recent 10 years and the 
2 patients with HIV etiology of their viral mfectious complications 
are registered in the first period of investigation, in the time when 
AIDS-testing had just been considered as obligatory examination 
in haemodialysis centers. The immunoreactivity type of 38 patients 
with viral mfections after renal allotransplantation shows lower activ- 
ity whlch could explain the easy-to-develop lnfectious process h m  
one hand, but fiom the other hand, it is obvious that those recipients 
show considerably less number of rejection episodes, compared to 
other patients with preliminary higher immunoreactivity status. Our 
model of immunologic monitoring allows a reliable prediction and 
differentiative magnosis of both, rejections and infections after renal 
allotransplantation. 
(p10411 Association of Cytornegalovirus (CMV)-specific 
Cytotoxic T-Cell (CTL) Activity with PCR-based 
Detection of CMV in Blood and with CMV 
Disease after Renal Transplantation (RTx) 
F! Reusser, R. Attenhofer, G. Cathomas, M. Tamm, G. Thiel 
University Hospital, Basel, Switzerland 
CMV-specific HLA class I-restricted CD8' CTL are thought to 
play an important role in controlling CMV mfection and disease. 
PCR-based detection of CMV DNA in blood specimens per- 
mits recognition of CMV infection at an early stage. We stud- 
ied 20 patients (pa) during the first 3 months after RTx who 
were CMV-seropositive before RTx (18 pts) or seronegative with a 
seropositive kidney donor (2 pts). The CMV-specific CTL response 
in peripheral blood was assessed at 1, 2, and 3 months after RTx. 
Blood mononuclear cells were co-cultured with CMV-infected au- 
tologous fibroblasts for 2 weeks, and then tested by C?'-release assay 
for cytotoxicity against CMV-infected or d e c t e d  autologous or 
HLA-mismatched fibroblasts. The PCR was used for detection of 
CMV DNA in blood leukocytes once a week. The assay was consid- 
ered positive if 2 2  consecutive blood specimens were PCR-positive. 
In the first 3 months after RTx, a CMV-specific CTL activity was 
demonstrable in 11/20 pts (55%), and CMV DNA was detectable in 
the blood of 18/20 pts (90%) at a median (range) of 23.5 days (8-46). 
There was no association between the presence of CMV-specific 
CTLs and of CMV DNA in blood during the month of first CTL 
detection (P = 0.2). CMV ctsease developed in 7/20 pts (35%). 
There was an inverse correlation between the presence of a specific 
CTL response and of CMV &ease after RTx (P = 0.04). 
In conclusion, CMV-specific CTLs do not appear to suppress 
CMV lnfection as detected by PCR in peripheral blood during the 
first 3 months after RTx. By contrast, a CMV-specific CTL response 
mediates protection h m  CMV disease during this period after RTx. 
Significance of EBV Status and PTLD in Adult 
Cardiac Transplantation 
RJ. Koerner, J.S. Harwood, EK. Gould, A. McMaster, 
R. Freeman, A.A. Codd, J. Forty, J.H. Dark. Freeman Hospital, 
Newcastle upon Tyne, United Kingdom 
Objective: Determination of the relation of Epstein-Ban virus (EBV) 
matchmg between heart transplant donor and recipient and the in- 
cidence of EBV associated post-transplantation lymphoproliferative 
disorder (PTLD). 
Method The initial EBV status of both donor and recipient of 
378 adult heart transplants was determined by teshng the EBV viral 
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capsid antigen (VCA) IgG status retrospectively. The EBV IgM status 
was determined h m  6 weeks post transplant in EBV IgG negative 
recipients. 
Results: 366 donorlrecipient pairs were tested for EBV IgG. 
12 patients lacking sdicient specimen for testing were excluded. 
Of the 366 cases tested, 330 (90%) both recipient and donor were 
found to be EBV IgG positive, 27 (7%) recipient EBV IgG positive 
and donor EBV IgG negative, 2 (1%) both recipient and donor EBV 
IgG negative. 7 (2%) were EBV IgG negative but received organs 
&om EBV IgG positive donors. 3 patients sen-converted to EBV 
I@, 2 patients remain EBV IgM negative. F'TLD was dmgnosed in 
12 (3%) of the 366 patients of which only 1 was EBV IgG negative 
but received an organ h m  a EBV IgG positive donor. This pa- 
tient sem-converted to EBV IgM positive 4 months post transplant, 
shortly before the +osis of PTLD. Of the 11 patients with PTLD 
who were EBV IgG positive preuansplant, 9 received organs h m  
positive donors. Serological evidence of EBV reactivation could be 
demonstrated in 7 (53%) of these patients shortly before the dmgno- 
sis of PTLD. No s imcan t  dXerence in the incidence of PTLD was 
found between both groups (p > 1). 
Conclusions: 1. EBV matching does not reduce the incidence of 
PTLD 2. Changes in EBV serology are not predictive of subsequent 
PTLD. 
(p10431 Infections in the lntrathoracic Organ 
Transplantation 
F! Suwangool, F!P Suwangool. Chulalongkorn University Hospital, 
Bangkok, Thailand 
Objective: To study the cause of death due to infection in intratho- 
racic organ transplantation. 
Methods: Prospective study all cases, by cultures, biopsies, 
necropsies or autopsies. 
Infection is a major complication and cause of death in organ 
transplantation. By December 1996, 36 heart transplantation, 13 
heart-lung and 6 lung transplantations had been performed at Chu- 
lalongkorn Hospital. In study of infections in the biopsies, necmpsies 
and autopsies of these patients, disseminated tuberculosis was seen in 
2 patients, one in heart transplant who lived 20 months after oper- 
ation, the other was a lung transplant who suMved 2 years and 2 
months following operations. Nocardia brain abscess was seen in one 
heart transplant patient. The other had severe-extensive bronchop- 
neumonia. Severe pneumonia was seen in 5 heart-lung aansplant, 3 
of these had CMV. Aspergdlosis was present in 3 patients, 2 of which 
also associated with CMV. Five of 6 lung transplant patients died of 
severe bacterial pneumonia, one of these had associated aspergdlosis. 
Conclusion: CMV and bacted pneumonia was the common 
cause of deaths. 
Advances in HIV 
I P10441 Induction of Immune Responses Against HIV-1 
Reverse Tmnscriptase by DNA Immunization 
M. Isaguhants 3,  S. Gudima ', M. Levi ', 0. Ivanova ' , 
D. Pokholok ', M. Garaev 
B. Wahren'. 'Iwtwvsky Institute of Krolw, Stockholm, Sweden, 
*Engelgardt Institute of Molecular Siolw, Moscow, Russia, 'Swedish 
Institute for Injiectious Diseaw Control, Stockholm, Sweden 
Objective: To induce immune responses ag&t HIV-1 reverse uan- 
scripmse. 
S. Kochetkov ', U. RudEn ', 
Methods: Plasmid DNA was constructed encoding HN-1 RT 
(66 kDa) under the control of CMV promoter (RT-DNA). Rabbits 
were immunized by intramascular injection of RT-DNA. A refer- 
ence immunization was done with p66 expressed in E coli. Immune 
responses were studied by ELISA, immunoblot, and PBMC prolif- 
eration tests using p66 and synthetic peptides. 
Results: DNA immunization induced potent humoral and cellu- 
lar anti RT responses. Mer 2 months anti RT titers reached 1:7000. 
Anti RT sera reacted with RT in immunoblot. Punfied anti RT IgG 
inhibited up to 30% of RT activity. Similar responses were induced 
by p66, but their fine specificity was di6erent: 
Epitope type Aa B-cell response T-cdl mponrc 
RTDNA p 6 6  R'CDNA p66 
CD4+- 36- 52 ++ +++ late 
Th 157-179 + ++ late C X l Y  
216290 ++ - cvly cvly 
375-389 - + klfc MN 
411425 ++ ++ ktc euty 
CTL 267-27 + - late M1V 
514-528 f f lo* MN 
291-305 f + hte htc 
341-356 + + late htc 
442425 ++ - late htc 
B-cell 244-269 + ++ late e d y  
Comments 
cotnmon 
common 
umque 
unique 
common 
UNqUC 
umque 
common 
common 
common 
umwc 
Conclusions: Potent anti HIS-1 immune response of unique 
fine specificity was induced by immunization with DNA encoding 
HN-1 reverse tnnscriptase 
I PI045 I The Effect of Hib Immunization on H N  Viremia 
D. Dockrell 
S. Strickland *, C. Pomeny ', D. Persing 
'University ofMinnesoto, USA, 3Univem'ty of Kentub  USA 
Background: Cellular activation may increase HIV viral replica- 
tion and therefore viremia. Immunization of HIV-positive persons 
is recommended a p m t  infiuenza, pneumococcus and Haemophitus 
inauenzae Type b (Hib). Recent reports suggest that antigenic stirnu- 
lation caused by vaccines may lead to increased H N  viral replication 
and viral load. In this study we examined whether Hib immuniza- 
tion had any sigdicant effect on HIV RNA copy number, CD4 
count or p24 antigen levels one month after receiving one of three 
licensed Hib-conjugate vaccines. 
Methods: We retmspectively analyzed sera h m  53 HIS-positive 
individuals enrolled in a Hib-conjugate vaccine study. Subjects ran- 
domly received one dose of one of three licensed Hib-conjugate 
vaccines (Connaught, Merdc or Lederle). HIV RNA copy num- 
ber was determined by RT-PCR using the HIV Monitor assay 
(Roche). CD4 counts and p24 assays (Couker) were also performed. 
Samples were analyzed pre-immunization (baseline) and one month 
post-immunization. We had 90% power to detect a 1.23 log rise in 
RNA copy number. 
Results: 38/53 (72%) of those enrolled were receiving 
anti-retroviral therapy. 
in HIV Seropositiie Adults 
G. Poland', l? Mitchell ' , F! Wollan T. Smith I ,  
'Muyo Clinic, USA, 
Pre-immuniudon (man) Post-immunization (mean) 
HIV-1 R N A  capier/ml 15,556 
CD4 T-ceWd 289 
924 pg/ml 34.81 
15,073 
2% 
41.99 
Conclusion: No statistically s i d c a n t  Merences were seen in 
HIV RNA copy number, CD4 count or p24 antigen level one 
month &r Hib-conjugate immunization. Subgroup analysis ac- 
